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Abstract
Aims and background:  The Ki-67 is a nuclear antigen detected by the monoclonal antibody
MIB-1 and its Labeling Index (LI) is considered a marker of normal and abnormal cell proliferation.
Pituitary adenomas are generally well differentiated neoplasms, even if in about one third of cases
they are invasive of surrounding tissues. The aim of this study is to evaluate the correlation between
Ki-67 labelling index and tumor size of pituitary adenomas extimated by means CT and MRI and
confirmed at operation.
Methods:  Using the monoclonal antibody MIB-1, we evaluated the expression of Ki-67 in 121
anterior pituitary adenomas consecutively operated on in a 48-month period.
Results:  In relation to neuroradiological (CT and MRI) and surgically verified tumor size, we
identified 24 microadenomas, 27 intrasellar macroadenomas, 34 intra-suprasellar macroadenomas,
and 36 intra-supra-parasellar macroadenomas. The adenomas were non-infiltrating (76 cases) and
infiltrating (45 cases) adenomas. The wall of the cavernous sinus (CS) was infiltrated in 18 cases.
Forty-eight adenomas were non-functioning and 73 functioning. The overall mean ± SD Ki-67 LI
was 2.72 ± 2.49% (median 1.6). It was 2.59 ± 1.81 in microadenomas, 2.63 ± 3.45 in intrasellar
macroadenomas, 1.91 ± 2.11 in intra-suprasellar macroadenomas, and 3.29 ± 5.45 in intra-supra-
parasellar macroadenomas (p = 0.27). It was 3.73 ± 5.13% in infiltrating and 2.03 ± 2.41% in non-
infiltrating adenomas (p = 0.02), and 5.61 ± 7.19% in CS-infiltrating versus 2.09 ± 2.37% in CS-non-
infiltrating adenomas (p = 0.0005).
Conclusions:  Our preliminary results seem to exclude significative correlations between Ki-67
LI and tumor size of anterior pituitary adenomas, even if this index can be considered a useful
marker in the determination of the infiltrative behaviour of these tumors.
Introduction
Anterior pituitary adenomas have usually considered be-
nign tumors, even if in about 1/3 of cases they infiltrate
surrounding tissues, including the wall of cavernous si-
nus (CS) [1,2,4–7,18–20,23,25–27,30]. This local "ma-
lignancy" contributes to explain the possibility of relapse
even after a macroscopically total surgical excision of tu-
mor. As observed for other neoplasms, the determina-
tion of cell proliferation activity seems to be useful in
making prognosis also in anterior pituitary adenomas. In
particular, Ki-67 is a nuclear antigen expressed in the G1,
S, G2, and M phases of cellular cycle
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[17,21,22,24,29,32,34] and its Labeling Index (LI), now-
adays recognizable by means the monoclonal antibody
MIB-1 [21], is widely considered as a marker of cellular
proliferation (growth fraction).
The aim of this study is to investigate the relationship be-
tween proliferative activity of anterior pituitary adenom-
as, quantified with Ki-67 LI, and their size
neuroradiologically (CT and MRI) and surgically veri-
fied.
Materials and Methods
Patient characteristics
From July, 1994, to July, 1998, 121 patients suffering
from an anterior pituitary adenoma were consecutively
operated on. In all cases an evaluation of the the Ki-67 LI
of surgical specimens was performed by means the mon-
oclonal antibody MIB-1 [21].
The age ranged from 17 to 77 years (mean 43.1 ± 15.5, me-
dian 40). The M/F ratio was 1:1.42 (71 females and 50
males). In 21 cases one previous operation and in 2 cases
two previous operations for the treatment of the pituitary
adenoma had been performed elsewhere (total 23 cases).
A functioning adenoma, with clinically expressed hor-
monal dysfunction, was present in 69 patients (59.5%):
in 29 (42.0%) disturbances related to high level of serum
PRL were detected, in 28 (40.6%) acromegaly was diag-
nosed, and in 12 (17.4%) Cushing's disease was observed.
One patient had high pre-operative levels of FSH, with-
out correlated clinical symptoms and sign. The preoper-
ative hormone serum level was defined as the highest
value observed before surgery. Visual acuity and/or
campimetric disturbances were present in 55 cases
(45.5%). An intracranial hypertension syndrome was ob-
served in 6 cases (5.0%).
In all cases the neuroradiological diagnosis was obtained
using both contrast-enhanced cerebral CT scan and MRI.
In relation to the tumor size, the adenoma was consid-
ered: A) microadenoma (≤  10 mm in diameter), 24 cases
(19.8%); B) intrasellar macroadenoma, 27 cases (22.3%);
C) intra-suprasellar macroadenoma (with extension
above the sella turcica), 34 cases (28.1%), and D) intra-
supra-parasellar macroadenoma (with extension above
the sella and toward the cavernous sinus), 36 cases
(29.7%). The tumor size was confirmed in all cases by the
impression of surgeon at operation.
A transsphenoidal approach was used in 116 cases
(95.9%), whereas a craniotomy was performed in 5 cases
(4.1%). In 113 cases (93.4%) a macroscopically total re-
moval and in 8 (6.6%) a subtotal excision of tumor was
obtained. In relation to surgically verified infiltration of
sellar floor dura and bone, we identified 76 (60.3%) non-
infiltrating and 45 (39.7%) infiltrating adenomas. The
wall of cavernous sinus was infiltrated in 18 out of 45 cas-
es (14.9% of 121 total cases and 40.0% of 45 infiltrating
cases). Histological examination showed in all cases a
typical anterior pituitary adenoma. On the basis of im-
munohistochemical staining we recognized 48 (39.7%)
endocrine-inactive and 73 (60.3%) active adenomas (26
PRL, 24 GH, 12 ACTH, 7 mixed, 3 TSH, and 1 FSH).
Plurihormonal adenomas were classified according to
the predominant endocrine symptoms (in 4 cases GH-
and in 3 PRL-related disturbances). Twenty out of 29 pa-
tients (68.9%) with prolactinomas or with mixed adeno-
ma with prevalent PRL expression received pre-
operative medical therapy (bromocriptine).
Determination of the Ki-67 Labeling Index (MIB-1 immu-
nostaining)
The surgical specimens were routinely processed, fixed
in neutral buffered formalin, and embebbed in paraffin.
In order to evaluate the Ki-67 antigen staining, 5-mi-
crometer sections, previously mounted onto glass slides
and dried, were incubated overnight at 4°C in the MIB-1
antibody (Immunotech, Marseille, France) [21]. Immu-
nostaining was performed using the avidin-biotin-per-
oxidase method. Ten fields were selected in regions with
highest concentrations of MIB-1-positive nuclei and
were examinated at high power magnification (x400).
Each field corresponded to a total number of cells rang-
ing from 700 to 1000, in relation with the cellularity of
the tumor specimen (Fig. 1). Areas of necrosis, normal
adenohypophysial cells, and endothelial cells were ex-
luded from the evaluation. On considering 1000 cells
with "manual" counting, the Ki-67 Labeling Index has
been defined as the percentage of MIB-1 positive cells
(dense brown precipitate restricted to the nuclei).
Figure 1
MIB-1 immunostaining of a mixed (GH-PRL) infiltrating pitui-
tary adenoma (original maginification, × 400). A high propor-
tion of labeled nuclei are seen (Ki-67 LI = 10%).BMC Cancer 2001, 1:12 http://www.biomedcentral.com/1471-2407/1/12
Statistical analysis
Computer-assisted data analysis was performed with a
commercially available software (SPSS 6.0, SPSS Inc.,
Chicago, IL). The normal distribution of Ki-67LI values
was verified by using normal Q-Q plots, with the Blom's
method. The Χ 2 (1 or 2 df, continuity correction) and
ANOVA tests were used to identify the statistical signifi-
cance of differences of Ki-67 LI observed in relation to
functioning vs non functioning adenomas, presence or
not of pre-operative visual disturbances, neuroradiolog-
ical and surgical extimated volume of tumor, surgical in-
vasiveness, and infiltration of CS. Values are expressed
as the mean ± standard deviation (SD) of the mean; for
each comparison, a P value was obtained (significance, ≤
0.05).
Results
The overall mean Ki-67 LI 2.72% ± 2.49 (median 1.6;
range 0-31). In 7 patients the LI was ≥  10:2 ACTH, 2 GH,
2 PRL, and 1 GH-PRL secreting adenomas; 5 out 7 were
infiltrating, 4 of which were CS-infiltrating. In all cases
there was not present any histological finding of pituitary
carcinomas. We did not observe relevant differences of
index in relation to age, sex, previous operations, pres-
ence of pre-operative visual disturbances, and function-
ing activity of tumor (Tab.1). Also the differences of
index related to the neuroradiological and surgical exti-
mated tumor size were not significant. The Ki-67 LI was
2.59% ± 1.81 in microadenomas, 2.63% ± 3.45 in intrasel-
lar macroadenomas, 1.91% ± 2.11 in intra-suprasellar
macroadenomas, and 3.29% ± 5.45 in intra-supra-para-
sellar macroadenomas (p = 0.27).
Invasive adenomas has a Ki-67 LI of 3.73 ± 5.13% versus
2.03% ± 2.41 of non-invasive ones (p = 0.02); it was
5.61% ± 7.19 in CS-inffltrating adenomas and 2.09% ±
2.37 in CS-non-inffltrating ones (p = 0.0005).
Discussion
Pituitary tumors are usually classified in microadenomas
and macroadenomas [10,11]. In the first group the tumor
consists of a well circumscribed nodule smaller than 10
mm in diameter [9], whereas macroadenomas produce
enlargement of the contour of sella turcica [10,11]. Jules
Hardy [10] proposed a schematic radiological classifica-
tion of anterior pituitary adenomas as outlined by axial
and coronal views of CT scan, today appliable to MRI. He
divided pituitary tumors in "enclosed" (intrasellar ade-
nomas) and "invasive" (intrasellar and intra-extrasellar
adenomas). Enclosed adenomas are subdivided in Grade
0 (microadenomas). Grade I (macroadenoma with slight
lowering of the floor), and Grade II (macroadenoma en-
larging the sella, with intact floor). Invasive adenomas
are subdivided in Grade III (macroadenomas eroding the
floor) and Grade IV (macroadenoma destroying the
floor).
Pituitary adenomas may be associated with a suprasellar
extension, as well outlined by coronal CT scan and coro-
nal and sagittal MR images. Hardy [10] classified them in
five types: A) tumor bulging into the chiasmatic cistern;
B) tumor reaching the anterior third ventricle; C) huge
suprasellar extension filling entirely the third ventricle;
D) parasellar extension into the temporal, frontal, or
Table 1: Mean Ki-67 LIs of 121 anterior pituitary adenomas.
N. of cases Mean LI (%) P
All patients 121 2.72
Visual disturbances: yes 47 2.67
0.93
no 56 2.59
Functioning adenomas: yes 73 3.13
0.09
no 48 1.93
CT/MRI tumor size: microadenomas 24 2.59
Intrasellar macroadenomas 27 2.63 0.27
intra- suprasellar macroadenomas 34 1.91
intra- supra- parasellar macroadenomas 36 3.29
Infiltration of surrounding tissues: yes 45 3.73
0.02
no 76 2.03
Infiltration of CS: yes 18 5.61
0.0005
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posterior fossa; and E) lateral expansion towards the
cavernous sinus.
In order to simplify these classifications and to reduce
the number of subgroups for correlations with Ki-67 LI
values, we preferred to subdivide the tumors of our series
into microadenomas, intrasellar macroadenomas, intra-
suprasellar macroadenomas, and intra-supra-parasellar
adenomas, including in the last group also pituitary ade-
nomas infiltrating the wall of cavernous sinus.
The incidence of infiltration among anterior pituitary ad-
enomas varies among the different subtytpes [26,31],
also in relation to the criteria used to assess it. An infil-
trating behaviour has been demonstrated surgically in
about 35% and histologically (microscopic infiltration of
dura mater) in about 90% of pituitary adenomas [1,2,4–
6,12,15,16,18,20,25–27,30]. It seems reasonable that the
most reliable criterion of infiltration, with clinical and
prognostic usefulness, is the impression of surgeon dur-
ing operations [30].
Several cell cycle-specific nuclear antigens have been
recognized with various immunohistochemical methods,
allowing a reliable evaluation of tumor growth fraction.
In particular, Ki-67 is a nuclear antigen nowadays simply
recognized by monoclonal antibody MIB-1 [21], typically
expressed in proliferating cells during the G1, S, G2, and
M phases of the cell-cycle [17,21,22,24,29,21,34]. It
turned out to be useful in a number of human neoplasms
[3,8,13,33], providing information about cellular prolif-
eration rate and, thus, about long-term prognosis. It re-
vealed to be a practical method that can be used in the
routine histological evaluation of brain tumors and, also,
of anterior pituitary adenomas. A high growth fraction
expressed by a high Ki-67 LI should suggest a high pro-
liferative rate and, thus, tight clinical-radiological fol-
low-up, in relation to possible post-operative relapse of
adenoma [14].
Up to date, only few Authors reported limited experienc-
es regarding the evaluation of anterior pituitary adeno-
ma growth fraction based on the expression of the Ki-67
antigen, both using formalin-fixed tissue and in vitro cell
culture [1,2,5,6,17–19,28,30]. In particular, in a series of
70 anterior pituitary adenomas and of 7 carcinomas,
Thapar et al [30] reported mean MIB-1 values of 1.37% in
non-invasive adenomas, of 4.66% in invasive adenomas,
and of 11.91% in pituitary carcinomas (p < 0.01). Analo-
gously, in our series LI was 2.03% ± 2.41 in non-infiltrat-
ing and 3.73% ± 5.13 in infiltrating adenomas (p = 0.02);
moreover, we observed a mean MIB-1 value of 5.61% ±
7.19 in CS-infiltrating versus 2.09% ± 2.37 in CS-non-in-
filtrating adenomas (p = 0.0005). In relation to the fre-
quency distribution of Ki-67 LIs in normal pituitary
glands, in non-invasive pituitary adenomas, in invasive
adenomas, and in pituitary carcinomas, Thapar et al [30]
established a value of 3% as the threshold LI for distin-
guishing non-invasive from invasive anterior pituitary
adenomas.
With te aim to establish a correlation between the growth
fraction of pituitary adenomas and their neuroradiologi-
cal and surgical extimated tumor size, we evaluated the
Ki67 LI by means te monoclonal antibody MIB-1 in 121
patients. As summarized in table 1, the values of mean
index were similar among microadenomas, intrasellar
macroadenomas, and intra-suprasellar macroadenom-
as. The mean LI of intra-supra-parasellar macroadeno-
mas (3.29%) was higher than others subgroups and than
the overall mean value (2.72%); this difference was not
statistically significant (p = 0.27) and presumably re-
flects the higher incidence of invasive tumors among in-
tra-supra-parasellar adenomas. Therefore, with the
exception of invasive adenomas, the different tumor size
of pituitary adenoma seems to be correlated to the time
of growth rather than to a different growth fraction
Conclusion
The evaluation of growth fraction of pituitary tumors,
identified by the Ki-67 nuclear antigen detected with the
MIB-1 monoclonal antibody, presumably gives further
information about their infiltrative behaviour. In our se-
ries of 121 cases, the analysis of proliferative rate seems
to exclude a definite correlation between the mean value
of Ki67 LI and the neuroradiological and surgical exti-
mated tumor size of anterior pituitary adenomas.
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